Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2012

01.02.2012 | Preclinical Study

Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas

verfasst von: Rozina Tufail, Mercy Jorda, Wei Zhao, Isildinha Reis, Zafar Nawaz

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Yes-associated protein (YAP) is a well characterized transcriptional coactivator that interacts with various transcription factors and modulates their transcriptional activities. Phosphorylation of YAP by specific kinases regulates its cellular distribution and transcriptional activation functions. Sequestration of phosphorylated YAP in cytoplasm results in the reduction of transcription from its target genes. Since, YAP has been characterized as a coactivator of estrogen (ER) and progesterone (PR) receptors, we examined the immunohistochemical expression profile of YAP and correlation of YAP expression with that of ER and PR in normal (40 samples) and tumor breast (226 samples) from microarray tissue samples using immunohistochemistry. Here we show that YAP expression is significantly reduced in invasive carcinoma samples compared to normal breast tissues, which express high levels of YAP (YAP was positive for 45.1% of invasive carcinoma samples versus 82.5% of normal samples P < 0.0001). Furthermore, the data shows that reduced expression of YAP in invasive carcinoma samples is significantly associated with ER negativity (YAP was negative for 59.9% in ER negative versus 38.9% in ER positive invasive carcinoma samples, P = 0.007) and PR negativity (YAP was negative for 60.1% in PR negative versus 28.9% in PR positive, P = 0.0004). Among invasive carcinoma samples, 42.9% were YAP, ER, and PR negative, whereas only 7.5% were found to be YAP, ER, and PR positive. On the contrary, 20 out of 23 (87%) normal breast tissues that were positive for ER and PR were also positive for YAP. These data suggest that YAP may act as a tumor suppressor in invasive breast carcinomas and it can also be used as a molecular marker for ER and PR negative breast tumors.
Literatur
1.
Zurück zum Zitat Sudol M (1994) Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 9:2145–2152PubMed Sudol M (1994) Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 9:2145–2152PubMed
2.
Zurück zum Zitat Sudol M, Recinos CC, Abraczinskas J, Humbert J, Farooq A (2005) WW or WoW: the WW domains in a union of bliss. IUBMB Life 57:773–778PubMedCrossRef Sudol M, Recinos CC, Abraczinskas J, Humbert J, Farooq A (2005) WW or WoW: the WW domains in a union of bliss. IUBMB Life 57:773–778PubMedCrossRef
3.
Zurück zum Zitat Sudol M, Sliwa K, Russo T (2001) Functions of WW domains in the nucleus. FEBS Lett 490:190–195PubMedCrossRef Sudol M, Sliwa K, Russo T (2001) Functions of WW domains in the nucleus. FEBS Lett 490:190–195PubMedCrossRef
4.
Zurück zum Zitat Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y (1999) A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 18:2551–2562PubMedCrossRef Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y (1999) A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 18:2551–2562PubMedCrossRef
6.
Zurück zum Zitat Basu S, Totty NF, Irwin MS, Sudol M, Downward J (2003) Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14–3-3 and attenuation of p73-mediated apoptosis. Mol Cell 11:11–23PubMedCrossRef Basu S, Totty NF, Irwin MS, Sudol M, Downward J (2003) Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14–3-3 and attenuation of p73-mediated apoptosis. Mol Cell 11:11–23PubMedCrossRef
7.
Zurück zum Zitat Overholtzer M, Zhang J, Smolen GA et al (2006) Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 103:12405–12410PubMedCrossRef Overholtzer M, Zhang J, Smolen GA et al (2006) Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 103:12405–12410PubMedCrossRef
8.
Zurück zum Zitat Steinhardt AA, Gayyed MF, Klein AP et al (2008) Expression of Yes-associated protein in common solid tumors. Hum Pathol 39:1582–1589PubMedCrossRef Steinhardt AA, Gayyed MF, Klein AP et al (2008) Expression of Yes-associated protein in common solid tumors. Hum Pathol 39:1582–1589PubMedCrossRef
9.
Zurück zum Zitat Strano S, Munarriz E, Rossi M et al (2001) Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 276:15164–15173PubMedCrossRef Strano S, Munarriz E, Rossi M et al (2001) Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 276:15164–15173PubMedCrossRef
10.
Zurück zum Zitat Zhao B, Ye X, Yu JD et al (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22:1962–1971PubMedCrossRef Zhao B, Ye X, Yu JD et al (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22:1962–1971PubMedCrossRef
11.
Zurück zum Zitat Ehsanian R, Brown M, Lu H et al (2010) YAP dysregulation by phosphorylation or DeltaNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene 29:6160–6171PubMedCrossRef Ehsanian R, Brown M, Lu H et al (2010) YAP dysregulation by phosphorylation or DeltaNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene 29:6160–6171PubMedCrossRef
12.
Zurück zum Zitat Yuan M, Tomlinson V, Lara R et al (2008) Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 15:1752–1759PubMedCrossRef Yuan M, Tomlinson V, Lara R et al (2008) Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 15:1752–1759PubMedCrossRef
13.
Zurück zum Zitat Allred DC, Wu Y, Mao S et al (2008) Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 14:370–378PubMedCrossRef Allred DC, Wu Y, Mao S et al (2008) Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 14:370–378PubMedCrossRef
15.
Zurück zum Zitat Horwitz K, Clarke C (1998) Estrogens and progestins in mammary development and neoplasia. Introduction. J Mammary Gland Biol Neoplasia 3:1–2PubMedCrossRef Horwitz K, Clarke C (1998) Estrogens and progestins in mammary development and neoplasia. Introduction. J Mammary Gland Biol Neoplasia 3:1–2PubMedCrossRef
16.
Zurück zum Zitat Naccarato AG, Viacava P, Vignati S et al (2000) Bio-morphological events in the development of the human female mammary gland from fetal age to puberty. Virchows Arch 436:431–438PubMedCrossRef Naccarato AG, Viacava P, Vignati S et al (2000) Bio-morphological events in the development of the human female mammary gland from fetal age to puberty. Virchows Arch 436:431–438PubMedCrossRef
17.
Zurück zum Zitat Bryan BB, Schnitt SJ, Collins LC (2006) Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 19:617–621PubMedCrossRef Bryan BB, Schnitt SJ, Collins LC (2006) Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 19:617–621PubMedCrossRef
18.
Zurück zum Zitat Benz CC, Scott GK, Sarup JC et al (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85–95PubMedCrossRef Benz CC, Scott GK, Sarup JC et al (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85–95PubMedCrossRef
19.
Zurück zum Zitat Clark GM, McGuire WL (1988) Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15:20–25PubMed Clark GM, McGuire WL (1988) Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15:20–25PubMed
20.
Zurück zum Zitat Clarke RB, Anderson E, Howell A (2004) Steroid receptors in human breast cancer. Trends Endocrinol Metab 15:316–323PubMedCrossRef Clarke RB, Anderson E, Howell A (2004) Steroid receptors in human breast cancer. Trends Endocrinol Metab 15:316–323PubMedCrossRef
21.
Zurück zum Zitat Putti TC, El-Rehim DM, Rakha EA et al (2005) Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18:26–35PubMedCrossRef Putti TC, El-Rehim DM, Rakha EA et al (2005) Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18:26–35PubMedCrossRef
22.
Zurück zum Zitat Dhananjayan SC, Ramamoorthy S, Khan OY et al (2006) WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors. Mol Endocrinol 20:2343–2354PubMedCrossRef Dhananjayan SC, Ramamoorthy S, Khan OY et al (2006) WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors. Mol Endocrinol 20:2343–2354PubMedCrossRef
23.
Zurück zum Zitat Zhao B, Wei X, Li W et al (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21:2747–2761PubMedCrossRef Zhao B, Wei X, Li W et al (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21:2747–2761PubMedCrossRef
24.
Zurück zum Zitat Kastner P, Krust A, Turcotte B et al (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603–1614PubMed Kastner P, Krust A, Turcotte B et al (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603–1614PubMed
25.
Zurück zum Zitat Khan OY, Fu G, Ismail A et al (2006) Multifunction steroid receptor coactivator, E6-associated protein, is involved in development of the prostate gland. Mol Endocrinol 20:544–559PubMedCrossRef Khan OY, Fu G, Ismail A et al (2006) Multifunction steroid receptor coactivator, E6-associated protein, is involved in development of the prostate gland. Mol Endocrinol 20:544–559PubMedCrossRef
26.
Zurück zum Zitat McKenna NJ, Xu J, Nawaz Z, Tsai SY, Tsai MJ, O’Malley BW (1999) Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol 69:3–12PubMedCrossRef McKenna NJ, Xu J, Nawaz Z, Tsai SY, Tsai MJ, O’Malley BW (1999) Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol 69:3–12PubMedCrossRef
27.
Zurück zum Zitat Bertini E, Oka T, Sudol M, Strano S, Blandino G (2009) YAP: at the crossroad between transformation and tumor suppression. Cell Cycle 8:49–57PubMedCrossRef Bertini E, Oka T, Sudol M, Strano S, Blandino G (2009) YAP: at the crossroad between transformation and tumor suppression. Cell Cycle 8:49–57PubMedCrossRef
Metadaten
Titel
Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas
verfasst von
Rozina Tufail
Mercy Jorda
Wei Zhao
Isildinha Reis
Zafar Nawaz
Publikationsdatum
01.02.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1435-0

Weitere Artikel der Ausgabe 3/2012

Breast Cancer Research and Treatment 3/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.